GSK targets Pfizer over newly approved RSV vaccine

07-08-2023

Sarah Speight

GSK targets Pfizer over newly approved RSV vaccine

MAXSHOT.PL / Shutterstock.com

GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.


GSK, Pfizer, RSV, respiratory syncytial virus, FDA, US

LSIPR